Harrow Inc (HROW)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione Frazionamento azionario

Precedente Chiudi:

Volume 24 ore:

Relative Volume:

Capitalizzazione di mercato:

Utile/perdita netta:

Rapporto P/E:

Flusso di cassa netto:

1 W Prestazione:

1M Prestazione:

6M Prestazione:

1 anno Prestazione:

Intervallo 1D:

Intervallo di 1 settimana:

Portata 52W:

Harrow Inc Stock (HROW) Company Profile

Healthcare (1052)

615.733.4731

1A BURTON HILLS BLVD, NASHVILLE, CA

Prossima data di guadagno

Ultimi documenti SEC

HROW's Discussions on Twitter

Compare HROW vs TAK, TEVA, HLN, ZTS, UTHR

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
HROW Harrow Inc	28.40	1.06B	272.30M	-5.14M	42.76M	-0.1635
TAK Takeda Pharmaceutical Co Adr	20.91	66.79B	29.91B	1.30B	3.49B	0.4056
TEVA Teva Pharmaceutical Industries Ltd Adr	41.70	48.63B	17.53B	1.58B	444.18M	1.3457
HLN Haleon Plc Adr	8.64	38.00B	14.54B	2.22B	2.58B	0.4871
ZTS Zoetis Inc	79.52	32.86B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	602.14	25.83B	3.17B	1.29B	1.01B	27.09

Harrow Inc Stock (HROW) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-09-09	Iniziato	Leerink Partners	Outperform
2025-07-11	Iniziato	Cantor Fitzgerald	Overweight
2025-06-12	Iniziato	BTIG Research	Buy
2025-06-10	Iniziato	William Blair	Outperform
2025-02-06	Iniziato	H.C. Wainwright	Buy
2024-12-04	Reiterato	B. Riley Securities	Buy
2024-04-11	Iniziato	Craig Hallum	Buy
2022-09-08	Ripresa	B. Riley Securities	Buy
2021-10-14	Ripresa	B. Riley Securities	Buy
2021-09-24	Iniziato	Aegis Capital	Buy
2021-07-02	Iniziato	Ladenburg Thalmann	Buy

Mostra tutto

Harrow Inc Borsa (HROW) Ultime notizie

Harrow Inc Azioni (HROW) Dati Finanziari

Harrow Inc Azioni (HROW) insider trading

Commercio interno	Relazione	Data	Transazione	Costo	#Azioni	Valore ($)	#Azioni Totale
Shojaei Amir	CHIEF SCIENTIFIC OFFICER	Aug 14 '26	Option Exercise	35.96	11,250	404,550	11,250
Shojaei Amir	CHIEF SCIENTIFIC OFFICER	Aug 14 '26	Sale	40.00	11,250	450,000	0
Graves Adrienne L	Director	May 18 '26	Buy	31.07	1,000	31,070	1,000
SILVERNAIL LAUREN P	Director	May 18 '26	Buy	31.00	1,000	31,000	1,000
BAUM MARK L	CHIEF EXECUTIVE OFFICER	May 14 '26	Buy	30.20	10,000	302,000	2,996,130
BOLL ANDREW R.	PRESIDENT AND CFO	May 14 '26	Buy	29.90	3,500	104,650	814,679
Opaleye Management Inc.	10% Owner	Mar 04 '26	Sale	39.67	138,263	5,485,184	59,428
Opaleye Management Inc.	10% Owner	Mar 03 '26	Sale	39.15	60,309	2,361,242	63,691
Opaleye Management Inc.	10% Owner	Feb 27 '26	Sale	54.18	5,000	270,900	65,000
Opaleye Management Inc.	10% Owner	Jan 06 '26	Sale	53.35	20,000	1,066,914	70,000

Harrow Inc (HROW)

Harrow Inc Stock (HROW) Company Profile

Compare HROW vs TAK, TEVA, HLN, ZTS, UTHR

Harrow Inc Stock (HROW) Upgrades & Downgrades

Harrow Inc Borsa (HROW) Ultime notizie

Harrow, Inc. (HROW) stock price, news, quote and history - Yahoo Finance UK

Harrow Inc. (HROW) Climbs 5.54% as Shares Reclaim Ground Toward $30 ResistanceRetail Volume - https://www.dars.gov.et/

Harrow Inc. (HROW) Climbs 5.54% as Shares Reclaim Ground Toward $30 ResistanceUp Down Ratio - siam.in

Harrow stock seeks rebound - Nashville Post

Do Options Traders Know Something About Harrow Stock We Don't? - Zacks Investment Research

Viatris Inc. (VTRS) Stock Price, News, Quote & History - Yahoo! Finance Canada

TYRVAYA is the only FDA-approved nasal spray for dry eye. Harrow acquired its rights outside Japan. - Stock Titan

Ocular Therapeutix, Inc.Common Stock (NQ: OCUL - The Chronicle-Journal

Is Harrow Inc (HROW) a Bargain After 5.7% Drop? GF Value Says Un - GuruFocus

Harrow at Cantor healthcare conference: long view, bigger eye-care bet - investing.com

HROW Initiates Coverage On Harrow -- Outperform Rating by Leerin - GuruFocus

Harrow (NasdaqGM:HROW) Stock Forecast & Analyst Predictions - Simply Wall Street

Andrew R. Boll Assumes Principal Accounting Officer Role at Harrow (NASDAQ: HROW) - Kalkine Media

Harrow Inc. (HROW) Slides 2.96% to $37.4, Approaches Support at $35.53Risk Reward Setups - dars.gov.et

Harrow Inc. (HROW) Slides 2.96% to $37.4, Approaches Support at $35.53Tick Index - dars.gov.et

Andrew R. Boll named Harrow principal accounting officer as Randall E. Pollard departs - TradingView

Harrow, Inc. Announces Management Changes, Effective September 4, 2026 - marketscreener.com

Harrow Health Inc. (HROW) Shareholding Pattern – Promoters, FIIs & DIIs - valueresearchonline.com

HROW Q2 2026 Earnings: EPS Misses Estimates as Losses DeepenMid-Term Outlook - vinanet.vn

Harrow Health Inc. 8.625% Senior Notes due 2026 (HROWL) Key Financial Ratios – Valuation, Profitability & More - valueresearchonline.com

HROW Q2 2026 Earnings: EPS Misses Estimates as Losses DeepenEarnings Risk Report - dars.gov.et

Harrow Inc stock gains as analysts see strong revenue growth ahead - ad-hoc-news.de

Harrow Inc (HROW) Stock Up 5.6% and Still Undervalued -- GF Scor - GuruFocus

Harrow to Participate in Three Investor Conferences in September - GlobeNewswire

Harrow (HROW) Reported Positive IHEEZO Study Results In Intravitreal Injections - Sahm

Harrow (HROW) Quarterly Results: EPS Falls Short of Its Estimate in the Current Update; Price Move - vinanet.vn

Harrow (HROW) Quarterly Results: EPS Falls Short of Its Estimate in the Current Update; Price Move: Shares Move Lower 2.81% at the CloseEarnings Recovery Stocks - dars.gov.et

HROW | Harrow, Inc. Common Stock FinancialsRevenue Breakdown - Quiver Quantitative

Harrow’s Iheezo Cuts Eye-Injection Discomfort by More Than Half - Sahm

Harrow (NASDAQ: HROW) CSO sells 11,250 shares in August option trade - Stock Titan

Harrow (HROW) Outlook: Ends Down by 2.64% at $40.95 for the Current Session; Next Session: Price Remains Between $38.90 Support and $43.00 Resistance on the DayShort Term Trading Ideas - vinanet.vn

What's Going On With Harrow Stock Friday?Harrow (NASDAQ:HROW) - Benzinga

Harrow Announces IHEEZO® Data in Patient-Reported Discomfort Following Intravitreal Injections - Sahm

Harrow (HROW): Strong Product Momentum Meets A Steep H2 Revenue Target - Yahoo Finance

In a 50-patient study, Harrow’s eye gel was linked to about 58% less injection discomfort - Stock Titan

Harrow (HROW) Reaffirms 2026 Guidance, Is The Upside Already Priced In? - simplywall.st

Harrow And 2 Other Growth Stocks Insiders Are Betting On - simplywall.st

Nutrien (NTR) Results Review: EPS Misses Its Estimate in the Available Record; Trading Response: Shares Move 1.59% Up in the Current UpdatePositive Surprise Momentum - dars.gov.et

Harrow CSO Amir Shojaei sells $450,000 in company stock By Investing.com - Investing.com South Africa

Harrow CSO Amir Shojaei sells $450,000 in company stock - Investing.com

Harrow CSO Amir Shojaei sells $450,000 in company stock By Investing.com - Investing.com Canada

Harrow CSO Amir Shojaei sells $450,000 in company stock By Investing.com - Investing.com India

Harrow CSO Amir Shojaei sells $450,000 in company stock - Investing.com

Rice Hall James & Associates LLC Takes Position in Harrow, Inc. $HROW - MarketBeat

Will Harrow’s (HROW) TYRVAYA Deal and Reaffirmed 2026 Guidance Redefine Its Dry Eye Strategy? - simplywall.st

Harrow (HROW) Q2 2026 Earnings Call Transcript - The Globe and Mail

Harrow (NASDAQ:HROW) Insider Amir Shojaei Sells 11,250 Shares - MarketBeat

Harrow Inc. (HROW) Slips 1.79% as Shares Test Key Support ZoneLast Point Resistance - vinanet.vn

Harrow Inc. (HROW) Slips 1.79% as Shares Test Key Support ZoneSweep Order Flow - dars.gov.et

HROW Q2 2026 Earnings: Wider Loss of $0.34 per Share Misses Estimates by 85.19%, but Stock Rises 2.98 - vinanet.vn

Harrow Inc Azioni (HROW) Dati Finanziari

Reddito

Reddito netto

Flusso di cassa

EPS

Harrow Inc Azioni (HROW) insider trading

Simile a HROW